ABSTRACT
INTRODUCTION
The mechanisms mediating hepatocellular injury in chronic hepatitis C infection are not completely clear. Evidence suggests that both a direct viral cytopathic injury and immunologically mediated hepatocellular damage occur (12, 13, 18) . The role of the level of HCV RNA in serum in affecting the progression of hepatitis and its prognosis is still unclear (2) . However higher levels of HCV RNA are associated with lower rate of response to interferon therapy (4, 7, 19, 20) . In addition, some HCV virus genotypes can be associated with higher viraemia levels (5, 8, 11) . Quantitative evaluation of serum HCV RNA appears to be of importance in the management of the patient (9) and it has been suggested as a parameter to decide what doses of IFN should be employed (3) . It is assumed that liver concentration reflects serum concentration. However, there are few studies in which HCV RNA has been simultaneously quantitated in serum and liver samples (1, 6, 10, 14, 17) . Moreover, the disease is complex, and both hepatic and extrahepatic sites of replication may contribute to the viral levels observed in serum. In addition, the relation between liver HCV RNA viral load and activity or stage of the liver disease remains unclear.
The objectives of the present work were to assess the feasibility of measuring HCV RNA levels in small tissue samples from percutaneous liver biopsies and to study their correlation with the serum levels of HCV RNA in patients with chronic HCV liver disease. Additionally we evaluated the relation of viral load with the serum levels of aminotransferases and with the presence of hepatic cirrhosis.
PATIENTS AND METHODS

Patients and study design
The study population comprised 20 patients (14 men and 6 women aged 28 to 61 years, mean 43.5 years). All patients were anti-HCV positive by second generation ELISA (ORTHO diagnostics, Rariran, New Jersey, USA) and by RIBA-2 for at least 6 months. Written consent was obtained from all patients before the study, which was approved by the Ethics Committee of the Royal Free Hospital School of Medicine, London, England. The study was conducted in accordance with the Declaration of Helsinki.
Serum ALT and AST levels were measured in each patient to ascertain the biochemical activity of the disease. Serum and liver samples for quantitation of HCV RNA were obtained on the same day. Serum was stored at -20 o C. The liver samples were collected under strictly sterile conditions. A portion of the biopsy specimen was immediately frozen in liquid nitrogen and stored frozen at -70 o C until processed for quantitative HCV RNA assay, whilst the other fragment of the biopsy was processed for histology by routine methods. Liver samples were obtained from 14 patients submitted to percutaneous liver biopsies for diagnosis or clinical management and the remainder from liver explants in patients undergoing orthotopic liver transplantation (OLT).
Methods
HCV RNA measurement:
a) Serum: concentrations of HCV RNA were determined by the quantitative bDNA (version 1) signal amplification assay (Quantiplex HCV RNA assay, Chiron corporation) according to the manufacturer's instructions. This test is based upon specific hybridisation of virus RNA in the sample by synthetic oligonucleotides to the highly conserved 5-untranslated region and core gene of HCV RNA immobilised on the surface of a microwell plate. Synthetic bDNA amplifier molecules and multiple copies of an alkaline phosphataselinked probe are hybridised to the immobilised complex. The complex is incubated with a chemo-luminescent substrate and the light emission is measured, the signal being proportional to the level of target nucleic acid. The quantity of HCV RNA in the sample is determined from a standard curve. The detection limit of the test is 350,000 HCV RNA equivalents per mL. These measurements were corrected for possible differences in efficiency of measurement of HCV RNA of different genotypes (16) . b) Liver: the liver sample was weighed and homogenised and RNA was isolated according to the following procedure. The homogenisation was done using pellet pestle mixers and matched tubes to which guanidine HCl (6M) homogenization solution (0.5 mL per 25 mg of tissue or a final volume of 0.5 mL for smaller samples) was added. Sarcosyl (20%) was added in order to obtain a final concentration of 0.5%. After vortexing and holding at 2-8 o C for 5 minutes, the specimen was centrifuged (12,000 G x 1 minute) and the supernatant was collected. Ten microlitres of poly A (10 mg/mL) was added to each tube and the content was gently vortexed. A 0.25 mL amount of 100% ethanol was added to each tube and mixed very thoroughly. The preparation was left to stand at -20 o C overnight, centrifuged at 12,000 G for 20 minutes and the supernatant carefully aspirated. An additional amount of 0.5 mL 70% ethanol was added to each tube. The tubes were then vortexed and centrifuged again for 20 minutes. The supernatant was aspirated and the pellet dried down with a rotary vacuum apparatus. The samples were stored at -70 o C until processing and from this point, samples were processed in the same way as serum samples.
The results (Eq/gm) were calculated by multiplying the result by the luminometer measurement in Eq/mL by 100 and dividing by the number of mg of the liver biopsy specimen. Corrections for possible differences in efficiency of measurement of HCV RNA of different genotypes were done in a similar way as described for serum samples.
HCV genotyping
Nineteen patients were genotyped by restriction fragment length polymorphism (RFLP) (15) . The amplicons generated from the 5'noncoding region were digested with restriction enzymes HaeIII/RsaI and BstNI/HinfI and the products were analyzed to classify HCV into genotypes.
Statistical analysis
Data were analysed statistically by the Fisher exact test and MannWhitney U test and the correlation coefficients were determined.
RESULTS
HCV RNA was detected in 15 of 20 serum specimens and 19 of 20 liver samples by bDNA assay. The weight of the liver samples ranged from 3 to 17 mg (mean ± SD = 5.64 ± 3.67 mg) when the material was collected by percutaneous liver biopsy and from 25 to 29 mg (mean ± SD = 27.8 ± 1.6 mg) when the specimens were obtained from liver explants. The only liver sample showing a negative result for bDNA was obtained by percutaneous biopsy; its weight was 8 mg. This patient was negative for HCV RNA in serum by bDNA as well, but tested positive for HCV RNA by RT-PCR.
The range and mean values of HCV RNA by bDNA assay in serum and liver are shown in Table 1 . RNA values were corrected for differences in efficiency of measurement of HCV RNA in types 1-6 (19) . Nineteen patients were genotyped, 12 were infected with HCV type 1, 6 with type 3 and 1 with type 5. No difference was observed between the levels of HCV RNA in serum or liver when comparing HCV type 1 and HCV type 3 ( Table 2 ).
There was a strong and significant correlation (r = 0.89; P <0.0001) between serum and liver HCV-RNA levels (Fig. 1) . Histopathological analysis showed chronic hepatitis in 12 patients and cirrhosis in 8. No difference was observed between cirrhotics and patients with chronic hepatitis regarding HCV RNA levels in the liver however cirrhotic patients showed lower serum HCV RNA concentrations (P = 0.001) ( Table 3 ). 
DISCUSSION
In this study we demonstrated that it is feasible to measure HCV RNA concentrations in small percutanous liver biopsy samples and there is a strong correlation between serum and liver HCV RNA levels. Our results were true after correction for differences in HCV RNA concentrations obtained using the bDNA (version 1) assay. The results support the hypothesis that serum levels of HCV RNA reflect those in the liver. Similar results were obtained by others (1, 10, 14, 17) . The present results demonstrate that quantitation of HCV RNA in serum provides information about HCV RNA in the liver and suggest that it is not usually necessary to measure hepatic HCV RNA concentrations to stratify treatment approaches. Thus they also support the concept that HCV RNA levels in serum, which reflect viral load in the liver, are valid measurements to predict the response to alphainterferon therapy and for planning drug treatment. Previous studies have not suggested that hepatic HCV RNA distribution between the right and left lobes of the liver will be a confounding variable (6) . Our study, similarly to others (1, 10, 14, 17) , has shown a significantly higher concentration of HCV RNA in liver tissue compared to serum. In view of this, measurement of serum viral load is representative of hepatic HCV RNA viral load albeit extrahepatic sites of replication may also contribute.
We did not observe any correlation between ALT and AST levels in the serum and HCV RNA levels in serum or liver.
Lower serum HCV RNA concentrations were observed in patients with cirrhosis in the liver biopsy. However, hepatic HCV RNA concentrations did not differ between cirrhosis and chronic hepatitis. It should be stressed, however, that the number of patients was relatively small, and the significance of this finding should be confirmed. A study of HCV RNA levels in liver samples with different degrees of severity of lesions may help to clarify the mechanisms involved in hepatocellular injury.
In conclusion, serum HCV RNA levels reflect liver HCV RNA levels, so that both can be used successfully in the management of patients with chronic HCV infection and to monitor their response to antiviral therapy. The strong correlation between serum and hepatic levels supports the employment of serum measurements, as they are more practical. 
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